The BrIDGs program assists researchers in advancing promising therapeutic agents through late-stage preclinical development toward an Investigational New Drug (IND) application and clinical testing. Learn more.
-
Research
-
- Funding & Notices
- News & Media
- About Translation
-
- About NCATS
-
NCATS Programs & Initiatives
- 3-D Tissue Bioprinting Program
- Assay Development and Screening Technology (ADST)
- Biomedical Data Translator
- Bridging Interventional Development Gaps (BrIDGs)
- Chemistry Technology
- Discovering New Therapeutic Uses for Existing Molecules
- Genetic and Rare Diseases Information Center (GARD)
- Matrix Combination Screening
- Early Translation Branch (ETB)
- A Specialized Platform for Innovative Research Exploration (ASPIRE)
- About NCATS
- Home
- About NCATS
- NCATS Programs & Initiatives
- Bridging Interventional Development Gaps (BrIDGs)
Bridging Interventional Development Gaps (BrIDGs)
Team Develops Potential New Approach to Stop Cancer MetastasisNCATS scientists collaborated with NCI and Northwestern University researchers to identify a new compound that blocks the spread of several types of cancer in animal models.
About BrIDGsFind out more about the BrIDGs program and its role in advancing new therapeutics.
Scientific CapabilitiesBrIDGs offers state-of-the-art expertise and resources for preclinical development.
Work with BrIDGsLearn how to collaborate with the BrIDGs program and access crucial resources.
BrIDGs ProjectsExplore active and completed preclinical development projects supported by BrIDGs.
Find out more about the BrIDGs program and its role in advancing new therapeutics.
BrIDGs offers state-of-the-art expertise and resources for preclinical development.
Learn how to collaborate with the BrIDGs program and access crucial resources.
Explore active and completed preclinical development projects supported by BrIDGs.
Work with Us
BrIDGs forms partnerships with researchers from academia, nonprofit organizations and pharmaceutical and biotechnology companies to complete preclinical development for promising therapeutic candidates. Learn more and contact BrIDGs.
Why BrIDGs Matters
As of fall 2015, BrIDGs has generated data to support 18 IND applications that have been cleared by the Food and Drug Administration and one clinical trial application cleared by Health Canada. A total of 14 projects have been evaluated in clinical trials. Five BrIDGs-supported agents have been evaluated in Phase II human clinical trials, in which researchers give an experimental therapy to a group of patients to evaluate the effectiveness and safety of a treatment. Third-party organizations have licensed or invested in 10 agents during or after their development by BrIDGs. Learn more about BrIDGs projects.
Thinking about applying?
NCATS Programs & Initiatives
- Funding & Notices
-